Recently, aldehyde dehydrogenase 1 (ALDH1) induction has been found to render lung adenocarcinomas resistant to EGFR-TKIs, and targeting ALDH1 has emerged as a novel strategy for treating lung cancer 2-4. Here, EGFR is linked to lung adenocarcinoma.